Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chasing the target: reports from the Advances in Targeted Therapies meeting, 2025.

Annals of the rheumatic diseases·2026
Same author

Correction: Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison.

Rheumatology and therapy·2026
Same author

Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double-Blind, Proof-of-Concept Study.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Bimekizumab safety and efficacy in patients with psoriatic arthritis: 3-year results from two phase 3 studies.

Rheumatology (Oxford, England)·2026
Same author

Bridging the gap: combining treat-to-target and difficult-to-treat strategies in the management of rheumatoid arthritis.

Nature reviews. Rheumatology·2026
Same author

Guselkumab Improves Patient-Reported Outcomes Among Participants with Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors in the COSMOS Study.

Rheumatology and therapy·2026

Related Experiment Video

Updated: Jul 8, 2026

Measuring Psoriasis Severity at Home
02:28

Measuring Psoriasis Severity at Home

Published on: March 1, 2024

Psoriatic arthritis: current topics.

David McCarey1, Iain B McInnes

  • 1Centre for Rheumatic Diseases, University of Glasgow, 10 Alexandra Parade, Glasgow, Scotland, G31 2ER, UK.

Current Rheumatology Reports
|January 8, 2008
PubMed
Summary

Psoriatic arthritis treatment shows promise with biologic therapies, particularly tumor necrosis factor-blocking agents. Research highlights T helper 17 immune responses in disease development and emerging genetic insights.

Area of Science:

  • Rheumatology
  • Immunology
  • Dermatology

Background:

  • Psoriatic arthritis affects 25% of psoriasis patients.
  • Recent therapeutic advances, especially biologic therapy, have spurred research.
  • Understanding pathogenesis and treatment is crucial.

Purpose of the Study:

  • To review recent investigations into psoriatic arthritis pathogenesis.
  • To summarize current clinical treatment strategies.
  • To highlight emerging genetic findings.

Main Methods:

  • Literature review of recent studies on psoriatic arthritis.
  • Analysis of clinical trial data for biologic therapies.
  • Examination of immunological and genetic research.

Related Experiment Videos

Last Updated: Jul 8, 2026

Measuring Psoriasis Severity at Home
02:28

Measuring Psoriasis Severity at Home

Published on: March 1, 2024

Main Results:

  • Biologic therapies, specifically TNF-blocking agents, show robust clinical responses, outperforming traditional DMARDs.
  • T helper 17-polarized immune responses are implicated in targeting skin, joints, and entheses.
  • Advanced genetic screening is revealing new insights into genetic antecedents.

Conclusions:

  • Biologic therapy represents a significant advancement in psoriatic arthritis treatment.
  • T helper 17 pathways are key targets for understanding disease mechanisms.
  • Further investigation into genetic factors is warranted.